KCC1 Activators
KCC1 Activators are a suite of chemical compounds that indirectly support the enhancement of KCC1 function through various cellular mechanisms. Compounds like VU0463271 and VU0240551, initially characterized by their action on KCC2, suggest a potential to induce a favorable conformation in KCC1, thus facilitating Cl^- ion extrusion. Bumetanide, although primarily an NKCC inhibitor, may indirectly elevate KCC1 function by optimizing the Cl^- ion gradient. DIOA, at lower doses, can trigger a rebound activation in KCC1, boosting its capacity for Cl^- transport. ML077, while a KCC2 activator, implies a possible indirect activation of KCC1 through modulation of Cl^- affinity. N-Ethylmaleimide and Ebselen, through their influence on cellular redox states, can provide an environment conducive to KCC1 activity enhancement, with the former targeting thiol groups and the latter mimicking glutathione peroxidase activity. Hydrochlorothiazide, by altering NaCl reabsorption, might create a compensatory response that upregulates KCC1 activity, and Quercetin's effect on membrane polarization could similarly enhance KCC1's functional role in Cl^- transport.
Further, the activity of KCC1 is influenced by the cellular ionic and redox landscapes, which are modulated by the remaining compounds. R(+)-IAA-94, although a known Cl^- channel inhibitor, may indirectly enhance KCC1 by adjusting cellular Cl^- balance, leading to a heightened activity state for the transporter. Zinc Pyrithione serves to increase intracellular zinc levels, which is known to regulate KCC function, thereby potentially boosting KCC1 activity. Withaferin A's interaction with cellular signaling pathways proposes another avenue for enhancing KCC1, particularly through the modulation of the redox environment that KCC1 is sensitive to. Collectively, these KCC1 Activators, through their indirect yet targeted influence on cellular ionic gradients, conformational states of transporters, and redox conditions, all contribute to the facilitation of optimal KCC1-mediated Cl^- ion transport without the need for direct activation or upregulation of the transporter itself.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $69.00 $214.00 $796.00 $1918.00 | 19 | |
NEM irreversibly activates K-Cl cotransporters by alkylating cysteine residues. This chemical modification results in a conformational change that maintains KCC1 in an active state, enhancing its ion transport function. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Although a broad-spectrum kinase inhibitor, at low doses staurosporine can selectively activate certain signaling pathways. This can lead to phosphorylation events that indirectly enhance the activity of KCC1 by affecting cellular ion balance. | ||||||
Riluzole | 1744-22-5 | sc-201081 sc-201081A sc-201081B sc-201081C | 20 mg 100 mg 1 g 25 g | $20.00 $193.00 $213.00 $317.00 | 1 | |
Riluzole is known to modulate neuronal excitability by impacting ion channels. Its action can result in altered intracellular Cl− concentration, which may indirectly upregulate KCC1 activity to re-establish ionic homeostasis. | ||||||
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $27.00 $79.00 $154.00 $309.00 | 1 | |
Flufenamic acid, a nonsteroidal anti-inflammatory drug, can activate Ca2+-activated Cl− channels. This could lead to a compensatory increase in KCC1 activity as the cell attempts to counterbalance the elevated intracellular Cl− levels. | ||||||
Chlorzoxazone | 95-25-0 | sc-211078 | 10 mg | $62.00 | ||
Chlorzoxazone, a muscle relaxant, can enhance KCC1 activity by activating the p38 MAPK pathway, which has been associated with the phosphorylation state and, consequently, the activity of K-Cl cotransporters. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $109.00 $228.00 | 9 | |
Bumetanide is a loop diuretic that inhibits the Na-K-2Cl cotransporter (NKCC). Chronic inhibition of NKCC can lead to compensatory upregulation of KCC1 activity as a homeostatic response to maintain intracellular Cl− levels. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin is a flavonoid with anti-inflammatory properties that can modulate various kinases and phosphatases. This modulation can affect the phosphorylation state of KCC1, thereby enhancing its activity. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone is a glucocorticoid that can modulate ion transporter expression. It may enhance KCC1 activity by inducing changes in gene expression profiles that favor the activation of ion transporters. | ||||||